CA2122519A1 - Cancer Treatment and Metastasis Prevention - Google Patents

Cancer Treatment and Metastasis Prevention

Info

Publication number
CA2122519A1
CA2122519A1 CA2122519A CA2122519A CA2122519A1 CA 2122519 A1 CA2122519 A1 CA 2122519A1 CA 2122519 A CA2122519 A CA 2122519A CA 2122519 A CA2122519 A CA 2122519A CA 2122519 A1 CA2122519 A1 CA 2122519A1
Authority
CA
Canada
Prior art keywords
hyaluronic acid
drug
daltons
cancer
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2122519A
Other languages
French (fr)
Other versions
CA2122519C (en
Inventor
Rudolf Edgar Dr. Falk
Samuel Simon Asculai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alchemia Oncology Pty Ltd
Original Assignee
NORPHARMCO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002122519A priority Critical patent/CA2122519C/en
Application filed by NORPHARMCO Inc filed Critical NORPHARMCO Inc
Priority to SK1379-96A priority patent/SK137996A3/en
Priority to KR1019960706101A priority patent/KR970702728A/en
Priority to HU9602965A priority patent/HUT75868A/en
Priority to CN95193689A priority patent/CN1151118A/en
Priority to JP7528564A priority patent/JPH09512797A/en
Priority to AU24023/95A priority patent/AU696373B2/en
Priority to CZ963089A priority patent/CZ308996A3/en
Priority to RU96122884/14A priority patent/RU2162327C2/en
Priority to PCT/CA1995/000259 priority patent/WO1995030423A2/en
Priority to EP95917846A priority patent/EP0760667A1/en
Publication of CA2122519A1 publication Critical patent/CA2122519A1/en
Application granted granted Critical
Publication of CA2122519C publication Critical patent/CA2122519C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A new method for the treatment of cancer in a human particularly malignant tumours, for example those in a breast or breasts, said method comprising the steps of:
(1) directly injecting into the tumour a dosage amount of a pharmaceutical composition comprising an effective amount of an anti-cancer drug and/or drug suitable for use to treat cancer (for example about 1 to about 2 mg Novantrone [tm] (Mitoxantrone), other chemotherapeutic agent, NSAIDs) and an effective amount of a form of hyaluronic acid, for example hyaluronic acid and/or pharmaceutically acceptable salts thereof preferably sodium hyaluronate having a molecular weight of less than 750,000 daltons (for example 150,000 - 225,000 daltons) (for example about 10 to about 20 mg sodium hyaluronate) in sterile water, and (2) administering systemically, preferably intravenously, a dosage amount of a pharmaceutical composition comprising (i) an effective amount of a form of hyaluronic acid (for example hyaluronic acid/or pharmaceutically acceptable and salts thereof preferably sodium hyaluronate having a molecular weight less than 750,000 daltons (for example 150,000 - 225,000 daltons) for example about 100 - 200 mg or more (because of a lack of toxicity and to reduce the side effects of any medicine (for example NSAID) administered therewith if the amount of the form of hyaluronic acid exceeds about 200 mg/70kg person) (ii) a drug selected from the group comprising (a) a non-steroidal anti-inflammatory drug (NSAID) for example in an amount of from about 30 mg to about 100 mg (for example 30 to 60 mg of tromethamine salt of ketoralac (sold under the trade mark Toradol) and 50 to 100 mg of diclofenac or diclofenac sodium (for example sold under the trade mark Voltarol);
(b) an anti-cancer drug, and (c) a drug suitable for use to treat cancer and combinations thereof optionally together with (iii) an anti-oxidant for example Vitamin C (in one embodiment 25 gm of Vitamin C).
CA002122519A 1991-07-03 1994-04-29 Cancer treatment and metastasis prevention Expired - Lifetime CA2122519C (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002122519A CA2122519C (en) 1994-04-29 1994-04-29 Cancer treatment and metastasis prevention
RU96122884/14A RU2162327C2 (en) 1994-04-29 1995-04-28 Treatment of cancer patient and prophylaxis of metastasis
HU9602965A HUT75868A (en) 1994-04-29 1995-04-28 Process for preparing pharmaceuticals with anti cancer activity
CN95193689A CN1151118A (en) 1994-04-29 1995-04-28 Cancer treatment and metatasis prevention
JP7528564A JPH09512797A (en) 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention
AU24023/95A AU696373B2 (en) 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention
SK1379-96A SK137996A3 (en) 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention
KR1019960706101A KR970702728A (en) 1994-04-29 1995-04-28 Cancer Treatment and Metastasis Prevention
PCT/CA1995/000259 WO1995030423A2 (en) 1991-07-03 1995-04-28 Cancer treatment and metastasis prevention
EP95917846A EP0760667A1 (en) 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention
CZ963089A CZ308996A3 (en) 1994-04-29 1995-04-28 Combination of dosing amounts of a pharmaceutical preparation for treating cancer in human, use of the dosing amount of a medicament against cancer and hyaluronic acid and pharmaceutical preparations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002122519A CA2122519C (en) 1994-04-29 1994-04-29 Cancer treatment and metastasis prevention

Publications (2)

Publication Number Publication Date
CA2122519A1 true CA2122519A1 (en) 1995-10-30
CA2122519C CA2122519C (en) 2001-02-20

Family

ID=4153495

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002122519A Expired - Lifetime CA2122519C (en) 1991-07-03 1994-04-29 Cancer treatment and metastasis prevention

Country Status (11)

Country Link
EP (1) EP0760667A1 (en)
JP (1) JPH09512797A (en)
KR (1) KR970702728A (en)
CN (1) CN1151118A (en)
AU (1) AU696373B2 (en)
CA (1) CA2122519C (en)
CZ (1) CZ308996A3 (en)
HU (1) HUT75868A (en)
RU (1) RU2162327C2 (en)
SK (1) SK137996A3 (en)
WO (1) WO1995030423A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301209A1 (en) * 2000-07-14 2003-04-16 Meditech Research Limited Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
EP1532434A1 (en) * 2002-07-01 2005-05-25 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
US8623354B2 (en) 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US8741970B2 (en) 1999-01-13 2014-06-03 Alchemia Oncology Pty Limited Composition and method for the enhancement of the efficacy of drugs
US8937052B2 (en) 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US10219997B2 (en) 2006-09-22 2019-03-05 Kochi University Radiation sensitizer or anti-cancer chemotherapy sensitizer
US12109232B2 (en) 2013-02-15 2024-10-08 Kortuc Inc. Radiation/chemotherapy sensitizer to be used for intratumoral local injection and for controlled release of hydrogen peroxide with hydrogel as carrier

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
CA2175282A1 (en) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
CA2208924A1 (en) * 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
US7151099B2 (en) 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
EA003256B1 (en) * 1997-08-29 2003-02-27 Байоджен, Инк. METHOD FOR TREATING MALIGNANT TUMOR BY IN VIVO GENE THERAPY WITH USE OF GENES ENCODING INTERFERON-beta
WO2000048597A1 (en) 1999-02-18 2000-08-24 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
EP1250152B1 (en) 1999-12-28 2013-05-15 Bioniche Urology IP Inc. Synergistic composition containing hyaluronic acid in the treatment of cancer
US6641571B2 (en) 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US20060003027A1 (en) * 2004-06-30 2006-01-05 Zhou James H Composition and method for reducing side effects of indole-3-carbinol and derivatives
KR100856114B1 (en) * 2008-04-18 2008-09-02 강지민 Sending and receiving method for sound and data of television using remote control
RU2523339C2 (en) * 2008-11-14 2014-07-20 Хистоджен, Инк. Extracellular matrix compositions for treating cancer
FR2994846B1 (en) 2012-08-29 2014-12-26 Vivacy Lab COMPOSITION, STERILIZED, COMPRISING AT LEAST ONE HYALURONIC ACID AND MAGNESIUM ASCORBYL PHOSPHATE
RU2586043C1 (en) * 2014-11-12 2016-06-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Method for prevention and treatment of complications in radiation therapy of skin cancer
RU2723883C2 (en) * 2018-07-17 2020-06-18 Николай Васильевич Цугленок Method for initiating death of tumour cells with ascorbic acid and hydroside with 3-aminophthalic acid and hf- and microwave energy wave radiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
CA2097892A1 (en) * 1993-06-07 1994-12-07 Rudolf Edgar Falk Prevention and control of cancer

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741970B2 (en) 1999-01-13 2014-06-03 Alchemia Oncology Pty Limited Composition and method for the enhancement of the efficacy of drugs
US8287894B2 (en) 2000-07-14 2012-10-16 Alchemia Oncology Pty Limited Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease
EP1301209A4 (en) * 2000-07-14 2005-11-09 Meditech Res Ltd Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
EP1301209A1 (en) * 2000-07-14 2003-04-16 Meditech Research Limited Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US8388993B2 (en) 2000-07-14 2013-03-05 Alchemia Oncology Pty Limited Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
EP1532434A4 (en) * 2002-07-01 2009-05-27 Univ Tufts Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
US8093217B2 (en) 2002-07-01 2012-01-10 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
EP2434282A3 (en) * 2002-07-01 2012-08-22 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
EP1532434A1 (en) * 2002-07-01 2005-05-25 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
US8937052B2 (en) 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8623354B2 (en) 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US10219997B2 (en) 2006-09-22 2019-03-05 Kochi University Radiation sensitizer or anti-cancer chemotherapy sensitizer
US12109232B2 (en) 2013-02-15 2024-10-08 Kortuc Inc. Radiation/chemotherapy sensitizer to be used for intratumoral local injection and for controlled release of hydrogen peroxide with hydrogel as carrier

Also Published As

Publication number Publication date
HUT75868A (en) 1997-05-28
EP0760667A1 (en) 1997-03-12
HU9602965D0 (en) 1997-01-28
AU2402395A (en) 1995-11-29
AU696373B2 (en) 1998-09-10
CN1151118A (en) 1997-06-04
KR970702728A (en) 1997-06-10
RU2162327C2 (en) 2001-01-27
JPH09512797A (en) 1997-12-22
WO1995030423A3 (en) 1995-12-21
SK137996A3 (en) 1998-08-05
WO1995030423A2 (en) 1995-11-16
CA2122519C (en) 2001-02-20
CZ308996A3 (en) 1998-01-14

Similar Documents

Publication Publication Date Title
CA2122519A1 (en) Cancer Treatment and Metastasis Prevention
US6656925B2 (en) Composition and method of treating arthritis
EP1997478B1 (en) Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US5859060A (en) Timed release tablet comprising naproxen and pseudoepherine
RU96122884A (en) HUMAN CANCER TREATMENT METHOD
US20040162269A1 (en) Composition and method of treating arthritis
US6608041B2 (en) Analgesics combined with naturally-occurring chondroprotective agents
WO2019155389A1 (en) An aqueous mucoadhesive and bioadhesive composition for the treatment
JPH10504828A (en) Hyaluronic acid and its derivatives for regulating cell activity
Oguchi et al. Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis
JPH07507054A (en) Topical composition containing hyaluronic acid and NSAIDS (non-steroidal anti-inflammatory drugs)
AR011133A1 (en) CONTROLLED RELEASE MICROGRANULES CONTAINING CISPLATINE, PROCEDURE FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION AND USE IN THE MANUFACTURE OF A POLYCHIMOTHERAPY MEDICATION OR IN ASSOCIATION WITH RADIOTHERAPY.
RU95101385A (en) Products containing g-csf and tnf-binding protein
CA2175282A1 (en) Use of forms of hyaluronic acid (ha) for the treatment of cancer
Cho et al. Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model
CA2561082C (en) Anti-inflammatory treatment based on strontium compounds
AU2010274030B2 (en) Treating patients with intravenous ibuprofen
CA1149284A (en) Pharmaceutical composition for treating neoplastic diseases and methods of preparation
Markman et al. Cisplatin and cytarabine administered intrapleurally as treatment of malignant pleural effusions
AU707467B2 (en) Nasal administration of agents for treatment of delayed onset emesis
US20110117070A1 (en) Compositions and methods for treating headache
EP0338679A2 (en) Tumour necrosis factor in the treatment of bladder cancer
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
AU727001B2 (en) Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS)
US5817644A (en) Targeting of dosages of medicine and therapeutic agents

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140429